CSI Market
Sign In | Register

Coherus Oncology inc (CHRS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CHRS quarterly Cash Flow →
Reviewing cash flow figures over time highlights how Coherus Oncology inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income168.02
Depreciation & amortization3.92
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-17.11
R & D, Environmental and Other Expense0.00
Gain (Loss) on Sale of Assets and Asset Impairment Charges0.00
Share-based Compensation16.97
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Fair Value Of Warrants In Excess Of Debt Proceeds Recognized At Issuance-
Fair Value Of Embedded Derivatives In Excess Of Debt Proceeds Recognized At Issuance-
Increase Decrease In Advance Payments Under License Agreement-
Non Cash Bonus Payment Settled In Common Stock-
Excess And Obsolete Inventory-
Non Cash Operating Lease Expense-
Increase Decrease In Accrued Rebates Fees And Returns-
Increase Decrease In Accrued Compensation-3.77
Upfront License Fee Payments Related To License And Collaboration Arrangements-
Impairment Of Intangible Assets And Contingent Value Rights Liability-
Gain Loss On Sale Of Interest In Projects-338.32
Change In Fair Value Of Derivatives12.61
Increase Decrease In Accrued Rebates Fees And Reserve-119.33
Income taxes-10.33
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables93.56
Increase (Decrease) in Accounts Payable, Trade-19.56
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-9.20
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets5.11
Other Working Capital64.45
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities14.45
Discontinued operations0.00
Net Cash flow from Operating Activities-138.51
Investing Activities
Capital Expenditures470.31
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities21.46
Payments to Acquire Marketable Securities-103.84
Real Estate Investments0.00
Payments To Acquire Interest In Related Party-
Upfront And Milestone Payments Related To License And Collaboration Arrangements-
Upfront And Milestone Based License Fee Payments Investing Activities-
Payments For Milestone Based License Fee-12.50
Increase in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Payments to Acquire Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities-0.34
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities375.09
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-233.19
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock8.25
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.12
Proceeds From Issuance Follow On Offering Net Of Underwriters Discounts And Commissions-
Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts And Commissions-
Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs-
Payments To Acquire Capped Call Options Related To Convertible Debt-
Finance Lease Principal Payments-
Proceeds From Revenue Purchase And Sale Agreement Net-
Proceeds From Repayments Of Revenue Purchase And Sale Agreement Net Of Issuance Costs-47.65
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-273.71
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow331.79
Total Cash Flow-37.13
4 historic quarters locked

Sign in to unlock the full Coherus Oncology inc cash flow history.

Sign In Create Free Account

About Coherus Oncology Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-025308

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License